Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
The goal of treatment of rheumatoid arthritis (RA) is to achieve remission or low disease activity. A wide range of disease-modifying antirheumatic drugs is used for the treatment of RA, including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). However,...
Saved in:
| Main Authors: | A. O. Bobkova, A. M. Lila |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2023-07-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1436 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01) -
The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01) -
The association between genetic characteristics and treatment failure when switching from biologic disease-modifying antirheumatic drugs/Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2025-02-01) -
Dynamics of global longitudinal strain of the left ventricular myocardium and blood biomarker levels in patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors
by: Yu. N. Gorbunova, et al.
Published: (2023-10-01) -
Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)